Prospects of immunotherapy for cancer
Zhinan Chen( )
National Translational Science Center for Molecular Medicine, Xi’an 710032, China; Department of Cell Biology, School of Basic Medicine, Fourth Military Medical University, Xi’an 710032, China
出版日期: 2019-03-12
Corresponding Author(s):
Zhinan Chen
1
CHJune, RS O’Connor, OUKawalekar, SGhassemi, MCMilone. CAR T cell immunotherapy for human cancer. Science 2018; 359(6382): 1361–1365
https://doi.org/10.1126/science.aar6711
pmid: 29567707
2
SBournazos, TT Wang, RDahan, JMaamary, JVRavetch. Signaling by antibodies: recent progress. Annu Rev Immunol 2017; 35(1): 285–311
https://doi.org/10.1146/annurev-immunol-051116-052433
pmid: 28446061
3
KNewick, S O’Brien, EMoon, SMAlbelda. CAR T cell therapy for solid tumors. Annu Rev Med 2017; 68(1): 139–152
https://doi.org/10.1146/annurev-med-062315-120245
pmid: 27860544
4
RALerner. Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol 2016; 16(8): 498–508
https://doi.org/10.1038/nri.2016.67
pmid: 27374636
5
JHPark, MB Geyer, RJBrentjens. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 2016; 127(26): 3312–3320
https://doi.org/10.1182/blood-2016-02-629063
pmid: 27207800
6
HJJackson, S Rafiq, RJBrentjens. Driving CAR T-cells forward. Nat Rev Clin Oncol 2016; 13(6): 370–383
https://doi.org/10.1038/nrclinonc.2016.36
pmid: 27000958
7
CARamos, HE Heslop, MKBrenner. CAR-T cell therapy for lymphoma. Annu Rev Med 2016; 67(1): 165–183
https://doi.org/10.1146/annurev-med-051914-021702
pmid: 26332003
Viewed
Full text
Abstract
Cited
Shared
Discussed